help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 17, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1824
A more recent version of this article appeared on January 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
92/1/59    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cawood, T J
Right arrow Articles by O'Shea, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cawood, T J
Right arrow Articles by O'Shea, D
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Smoking

Submitted on August 22, 2006
Accepted on October 11, 2006

Smoking and thyroid associated ophthalmopathy; a novel explanation of the biological link

T J Cawood*, P Moriarty, C O'Farrelly, and D O'Shea

Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland; Education and Research Centre, St. Vincent's University Hospital, Dublin, Ireland; Royal Victoria Eye and Ear Hospital, Dublin, Ireland; The Conway Institute, University College Dublin, Ireland

* To whom correspondence should be addressed. E-mail: tomjcawood{at}eircom.net.

Introduction: Cigarette smoking is the strongest modifiable risk factor for developing thyroid associated ophthalmopathy (TAO), and the severity of TAO is related to the current number of cigarettes smoked per day. We aimed to establish the effects of cigarette smoke extract (CSE) on an in vitro model of TAO.

Methods: Orbital tissue was taken during surgery from ten patients with TAO and nine control subjects. Orbital fibroblasts (OFs) were cultured, exposed to CSE, and inter-cellular adhesion molecule 1 (ICAM1) expression measured by flow cytometry. Glycosaminoglycan production was measured by hyaluronic acid ELISA. OFs were grown in adipogenic media ± CSE and/or IL1, and the degree of adipogenesis was quantified.

Results: Fibroblasts from patients with TAO and controls showed similar responses. ICAM1 expression was not affected by CSE. Hyaluronic acid production was stimulated by CSE in a dose-dependent manner (correlation coefficient 0.978, P = 0.022), with 5%CSE causing an increase of 44% (P = 0.001). CSE increased adipogenesis in a dose-related manner, as did IL1. The effects of CSE and IL1 on adipogenesis were synergistic, with the degree of adipogenesis in the well containing both 5%CSE and 0.1ng/ml IL1 being double the magnitude of the sum of the values obtained from either stimulus alone (P < 0.001). Addition of an anti-IL1 antibody to the well containing both 5%CSE and 0.1ng/ml IL1 reduced the degree of adipogenesis by 82% (P < 0.001).

Conclusion: These findings may help explain how cigarette smoking has a detrimental effect in TAO, and suggests that IL1 may be an attractive therapeutic target in TAO.


Key words: Thyroid associated ophthalmopathy • Graves' ophthalmopathy • Thyroid eye disease • Smoking • Anti-cytokine therapy







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society